KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Assets (2017 - 2025)

Historic Assets for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $3.6 billion.

  • Amneal Pharmaceuticals' Assets rose 401.32% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 401.32%. This contributed to the annual value of $3.5 billion for FY2024, which is 83.15% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Assets stood at $3.6 billion for Q3 2025, which was up 401.32% from $3.4 billion recorded in Q2 2025.
  • Amneal Pharmaceuticals' Assets' 5-year high stood at $4.0 billion during Q2 2022, with a 5-year trough of $3.4 billion in Q1 2025.
  • Moreover, its 5-year median value for Assets was $3.7 billion (2023), whereas its average is $3.7 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Assets crashed by 980.98% in 2021 and then surged by 401.32% in 2025.
  • Amneal Pharmaceuticals' Assets (Quarter) stood at $3.9 billion in 2021, then dropped by 3.56% to $3.8 billion in 2022, then dropped by 8.6% to $3.5 billion in 2023, then grew by 0.83% to $3.5 billion in 2024, then grew by 2.81% to $3.6 billion in 2025.
  • Its Assets was $3.6 billion in Q3 2025, compared to $3.4 billion in Q2 2025 and $3.4 billion in Q1 2025.